TrialPath
Recruiting

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

NCT06177015 · The First Affiliated Hospital with Nanjing Medical University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Randomized Controlled Study on the Efficacy and Safety of Intermittent Darolutamide Treatment in the Triple Therapy of Metastatic Hormone Sensitive Prostate Cancer
About this study
Patients will firstly receive 6 months of darolutamide in combination with docetaxel and ADT treatment. 1\. When the patient reaches: 1. PSA ≤ 0.2ng/ml 2. Or PSA \> 0.2ng/ml but with more that 90% decrease comparing baseline 3. Without newly discovered metastatic lesions. They will be randomly assigned in a 1:1 ratio to either continuous treatment group or intermittent treatment group (1) Continuous treatment group: Darolutamide: 600mg, bid+ADT: Leuprorelin (3.6mg qm or 10.8mg q3m) or goserelin 80mg qm until mCRPC; (2) Intermittent treatment group: Only ADT as background treatment without Darolutamide. PSA check every three months, when the patient's PSA \> 1ng/ml (or PSA \> 1ng/ml and PSA has risen by more than 20% comparing baseline), restart the darolutamide, until mCRPC. 2\. When the patient: 1. PSA \> 0.2ng/ml and has not decreased by 90% compared to baseline 2. Or has new metastatic lesions, they will exit the study. Imaging assessment will be conducted every 3 months
Eligibility criteria
Inclusion Criteria: Patients must meet all of the following criteria to be eligible for this study: 1. Male aged ≥18 years; 2. Histologically or cytologically confirmed prostate adenocarcinoma; 3. Metastatic disease (confirmed by conventional imaging); 4. ECOG performance status of 0-1; 5. Suitable for ADT and docetaxel treatment; 6. Good bone marrow, kidney, and liver function: 1\. (1) Hematological examination (no blood transfusion or use of hematopoietic growth factors within 7 days before screening): 1\. Hemoglobin (HB) ≥ 90g/L; 2. Absolute neutrophil count (ANC) ≥ 1.5×109/L; 3. Platelets (PLT) ≥ 80×109/L; 2. (2) Blood biochemistry examination (no blood transfusion or albumin within 7 days before screening): 1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN 2. Total bilirubin (TBIL) ≤ 2.0 × ULN; 3. Serum creatinine (Cr) ≤ 2.0×ULN; 7\. Willing to participate in this study, sign an informed consent form, and have good compliance Exclusion Criteria: 1. No metastatic disease; 2. Prior treatment with: a) Second-generation ARis or other experimental ARis b) CYP17 enzyme inhibitors such as abiraterone acetate or oral ketoconazole for anti-tumor treatment of prostate cancer c) Chemotherapy or immunotherapy prior to randomization for prostate cancer 3. Received radiotherapy within 2 weeks before starting 6 months of darolutamide + docetaxel + ADT treatment; 4. Stroke, myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass surgery, congestive heart failure (New York Heart Association class III or IV); 5. History of malignant tumors; 6. Planned receipt of other anti-tumor treatment during the study treatment period; 7. Known allergy to the above drug components; 8. Difficulty swallowing, chronic diarrhea, intestinal obstruction, and various factors affecting drug intake and absorption; 9. Refusal to sign the informed consent form; 10. Investigator's opinion that the participant is not suitable for inclusion.
Study design
Enrollment target: 200 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2023-12-11
Estimated completion: 2027-12-31
Last updated: 2023-12-26
Interventions
Drug: Darolutamide continuousDrug: Darolutamide intermittent
Primary outcomes
  • • Radiographic Progression Free Survival (36 months)
  • • Overall Survival (36 months)
Sponsor
The First Affiliated Hospital with Nanjing Medical University · other
Contacts & investigators
ContactShangqian Wang · contact · wsq5501@126.com · +862568303186
InvestigatorLixxin Hua · principal_investigator, Urology Dpt, First Affiliated Hospital of Nanjing Medical University
All locations (1)
Urology dpt, First Affiliated Hospital of Nanjing Medical UniversityRecruiting
Nanjing, Jiangsu, China